Haemonetics Co. (NYSE:HAE) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC reduced its holdings in shares of Haemonetics Co. (NYSE:HAE) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,740 shares of the medical instruments supplier’s stock after selling 1,092 shares during the quarter. Great Lakes Advisors LLC’s holdings in Haemonetics were worth $1,697,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in HAE. Wellington Management Group LLP lifted its holdings in shares of Haemonetics by 9.5% in the 3rd quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after purchasing an additional 363,702 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Haemonetics by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after purchasing an additional 21,547 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Haemonetics by 29.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock valued at $88,433,000 after purchasing an additional 250,833 shares during the last quarter. Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of Haemonetics by 10.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock valued at $66,206,000 after purchasing an additional 80,783 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on HAE. JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price for the company. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $95.00 to $68.00 in a report on Friday, February 7th. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Needham & Company LLC decreased their price objective on Haemonetics from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $101.67.

Haemonetics Stock Down 0.3 %

HAE opened at $65.76 on Friday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business has a 50 day simple moving average of $68.61 and a 200-day simple moving average of $75.41. The stock has a market capitalization of $3.30 billion, a P/E ratio of 25.89, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 12 month low of $58.80 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.